Docetaxel added to androgen deprivation therapy (ADT) was the most cost-effective first-line regimen for patients with ...

Significantly less progression, especially unstable lesions, with relugolix versus leuprol ...

In oligometastatic castration-resistant prostate cancer, the rationale to use local SBRT is improved disease control.

In a pooled analysis, longer duration of androgen deprivation therapy (ADT) was associated with nonlinear improvements in outcomes in men with prostate cancer receiving definitive radiotherapy.

ADT with leuprolide was tied to increased coronary plaque vs relugolix in prostate cancer. What does this mean for CV risk?

—As more men are cured of prostate cancer, or are long-term survivors, the challenges of survivorship are in the spotlight. Improved screening practices, earlier detection, and better therapies have ...

Prostate cancer is the most common cancer in men throughout the United States. Most men do not realize they have cancer due ...

PEACE-2 finds adding cabazitaxel to ADT plus radiotherapy fails to improve survival in high-risk localized prostate cancer, while increasing severe toxicities and deaths.

The REVELUTION (Relugolix versus Leuprolide Cardiac) trial compared coronary plaque after 2 types of androgen deprivation therapy (ADT) for prostate cancer.

Metformin did not prevent development of metabolic syndrome in men receiving androgen deprivation therapy for prostate cancer in a phase III trial. Metformin was associated with improvement in weight, ...

Overall these findings indicate that adding cabazitaxel to long-term androgen deprivation therapy and radiotherapy did not improve long-term outcomes and increased toxicity in men with high-risk ...